AC Immune to Participate in Upcoming Investor Conferences

Rhea-AI Summary

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases, has announced its participation in two major investor conferences in March 2025:

• Leerink Partners 2025 Global Healthcare Conference - Management will hold investor meetings on March 10, 2025
• Barclays 27th Annual Global Healthcare Conference - Management will conduct investor meetings on March 11, 2025

Interested parties can arrange one-on-one meetings with AC Immune's management team through their Leerink or Barclays representatives or by contacting AC Immune directly.

AC Immune to Participate in Upcoming Investor Conferences

Lausanne, Switzerland, March 4, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the company's management will participate in the following investor conferences in March:

• Leerink Partners 2025 Global Healthcare Conference,
  Management will participate in investor meetings on March 10, 2025
  
  
• Barclays 27th Annual Global Healthcare Conference,
  Management will participate in investor meetings on March 11, 2025
  
  

Please contact your Leerink or Barclays representative or AC Immune to request a one-on-one meeting with AC Immune’s management team at the conferences.

About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen^® and Morphomer^®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and more than $4.5 billion in potential milestone payments plus royalties.

SupraAntigen^® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer^® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.

The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

For further information, please contact:

Head of Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: investor@acimmune.com	U.S. Investors Christina Tartaglia Precision AQ Phone: +1 212 362 1200 Email: christina.tartaglia@precisionaq.com
International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com

Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Attachment

• 20250304_ACIU_Curtain raiser_Leerink and Barclays_final

FAQ

Which investor conferences will AC Immune (ACIU) attend in March 2025?

AC Immune will participate in the Leerink Partners 2025 Global Healthcare Conference on March 10 and the Barclays 27th Annual Global Healthcare Conference on March 11, 2025.

How can investors schedule meetings with AC Immune (ACIU) management at these conferences?

Investors can schedule meetings through their Leerink or Barclays representatives or by contacting AC Immune directly.

What is AC Immune's (ACIU) current business focus?

AC Immune is a clinical-stage biopharmaceutical company specializing in precision medicine for neurodegenerative diseases.

When will AC Immune (ACIU) participate in the Leerink Partners conference?

AC Immune management will participate in investor meetings at the Leerink Partners conference on March 10, 2025.